Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA
- PMID: 18596146
- PMCID: PMC2546754
- DOI: 10.1128/JCM.00265-08
Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA
Abstract
Glycopeptide-intermediate Staphylococcus aureus (GISA) and, in particular, heterogeneous GISA (hGISA) are difficult to detect by standard MIC methods, and thus, an accurate detection method for clinical practice and surveillances is needed. Two prototype Etest strips designed for hGISA/GISA resistance detection (GRD) were evaluated using a worldwide collection of hGISA/GISA strains covering the five major clonal lineages. A total of 150 strains comprising 15 GISA and 60 hGISA strains (defined by population analysis profiles-area under the curve [PAP-AUC]), 70 glycopeptide-susceptible S. aureus (GSSA) strains, and 5 S. aureus ATCC reference strains were tested. For standardized Etest vancomycin (VA) MIC testing, the modified Etest macromethod with VA and teicoplanin (TP) strips tested with a heavier inoculum using brain heart infusion agar (BHI) and two glycopeptide screening agar plates (6 microg/ml VA/BHI and 5 microg/ml Mueller-Hinton agar [MHA]) were tested in parallel with the two new Etest GRD strips: a VA 32 (0.5-microg/ml)-TP 32 (0.5-microg/ml) double-sided gradient (E-VA/TP) with one prototype overlaid with a nutrient (E-VA/TP+S) to enhance the growth of hGISA. The Etest GRD strips were tested with a standard 0.5-McFarland standard inoculum using MHA and MHA plus 5% blood (MHB) and were read at 18 to 24 and 48 h. The interpretive MIC cutoffs used for the new Etest GRD strips at 24 and 48 h were as follows: for GISA, TP or VA, >or=8, and a standard VA MIC of >or=6; for hGISA, TP or VA, >or=8, and a standard VA MIC of <or=4. The results on MHB at 48 h showed that E-VA/TP+S had high specificity (94%) and sensitivity (95%) in comparison to PAP-AUC and was able to detect all GISA (n = 15) and 98% of hGISA (n = 60) strains. In contrast, the glycopeptide screening plates performed poorly for hGISA. The new Etest GRD strip (E-VA/TP+S), utilizing standard media and inocula, is a simple and acceptable tool for detection of hGISA/GISA for clinical and epidemiologic purposes.
Figures



Similar articles
-
A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA).Ann Clin Microbiol Antimicrob. 2007 Sep 24;6:9. doi: 10.1186/1476-0711-6-9. Ann Clin Microbiol Antimicrob. 2007. PMID: 17892555 Free PMC article.
-
Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus.J Clin Microbiol. 2007 Oct;45(10):3263-9. doi: 10.1128/JCM.00836-07. Epub 2007 Aug 8. J Clin Microbiol. 2007. PMID: 17687008 Free PMC article.
-
[Endemic heteroresistant glycopeptide intermediate Staphylcoccus aureus (hGISA) comprising unrelated clonal types and not associated with vancomycin therapy].Pathol Biol (Paris). 2002 Nov;50(9):525-9. doi: 10.1016/s0369-8114(02)00345-0. Pathol Biol (Paris). 2002. PMID: 12490414 French.
-
Heterogeneous vancomycin resistance in Staphylococcus aureus: a review of epidemiology, diagnosis, and clinical significance.Ann Pharmacother. 2010 May;44(5):844-50. doi: 10.1345/aph.1M526. Epub 2010 Mar 23. Ann Pharmacother. 2010. PMID: 20332341 Review.
-
Low-level glycopeptide resistance in methicillin-resistant Staphylococcus aureus and how to test it.Clin Microbiol Infect. 2009 Dec;15 Suppl 7:2-9. doi: 10.1111/j.1469-0691.2009.03094.x. Clin Microbiol Infect. 2009. PMID: 19951328 Review.
Cited by
-
Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections.J Clin Microbiol. 2012 Aug;50(8):2548-52. doi: 10.1128/JCM.00775-12. Epub 2012 May 16. J Clin Microbiol. 2012. PMID: 22593595 Free PMC article. Review.
-
Adaptive physiological and metabolic alterations in Staphylococcus aureus evolution under vancomycin exposure.World J Microbiol Biotechnol. 2024 Sep 16;40(10):322. doi: 10.1007/s11274-024-04128-2. World J Microbiol Biotechnol. 2024. PMID: 39283509
-
Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States.J Clin Microbiol. 2011 Dec;49(12):4203-7. doi: 10.1128/JCM.01152-11. Epub 2011 Oct 5. J Clin Microbiol. 2011. PMID: 21976769 Free PMC article.
-
Vancomycin MIC Distribution among Methicillin-Resistant Staphylococcus Aureus. Is Reduced Vancomycin Susceptibility Related To MIC Creep?Open Access Maced J Med Sci. 2018 Dec 22;7(1):12-18. doi: 10.3889/oamjms.2019.009. eCollection 2019 Jan 15. Open Access Maced J Med Sci. 2018. PMID: 30740152 Free PMC article.
-
Resistance selection studies comparing the activity of razupenem (PTZ601) to vancomycin and linezolid against eight methicillin-resistant and two methicillin-susceptible Staphylococcus aureus strains.Antimicrob Agents Chemother. 2009 Jul;53(7):3118-21. doi: 10.1128/AAC.00183-09. Epub 2009 May 11. Antimicrob Agents Chemother. 2009. PMID: 19433566 Free PMC article.
References
-
- Anonymous. 2004. Vancomycin-resistant Staphylococcus aureus—New York, 2004. MMWR Morb. Mortal. Wkly. Rep. 53322-323. - PubMed
-
- Anonymous. 2002. Vancomycin-resistant Staphylococcus aureus—Pennsylvania, 2002. MMWR Morb. Mortal. Wkly. Rep. 51902. - PubMed
-
- Appelbaum, P. C. 2006. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 12(Suppl. 1)16-23. - PubMed
-
- Berger-Bachi, B. 2002. Resistance mechanisms of gram-positive bacteria. Int. J. Med. Microbiol. 29227-35. - PubMed
-
- Charles, P. G., P. B. Ward, P. D. Johnson, B. P. Howden, and M. L. Grayson. 2004. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin. Infect. Dis. 38448-451. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials